These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 32309672)

  • 1. Nonalcoholic steatohepatitis Fitness Intervention in Thrombosis (NASHFit): Study protocol for a randomized controlled trial of a supervised aerobic exercise program to reduce elevated clotting risk in patients with NASH.
    Stine JG; Schreibman I; Navabi S; Kang M; Dahmus J; Soriano C; Rivas G; Hummer B; Beyer M; Tressler H; Kimball SR; Patterson AD; Schmitz K; Sciamanna C
    Contemp Clin Trials Commun; 2020 Jun; 18():100560. PubMed ID: 32309672
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Lisboa QC; Nardelli MJ; Pereira PA; Miranda DM; Ribeiro SN; Costa RSN; Versiani CA; Vidigal PVT; Ferrari TCA; Couto CA
    World J Hepatol; 2020 Oct; 12(10):792-806. PubMed ID: 33200017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum Fibroblast Growth Factor 21 Is Markedly Decreased following Exercise Training in Patients with Biopsy-Proven Nonalcoholic Steatohepatitis.
    Stine JG; Welles JE; Keating S; Hussaini Z; Soriano C; Heinle JW; Geyer N; Chinchilli VM; Loomba R; Kimball SR
    Nutrients; 2023 Mar; 15(6):. PubMed ID: 36986211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utilization of a Directly Supervised Telehealth-Based Exercise Training Program in Patients With Nonalcoholic Steatohepatitis: Feasibility Study.
    Motz V; Faust A; Dahmus J; Stern B; Soriano C; Stine JG
    JMIR Form Res; 2021 Aug; 5(8):e30239. PubMed ID: 34402795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NASHFit: A randomized controlled trial of an exercise training program to reduce clotting risk in patients with NASH.
    Stine JG; Schreibman IR; Faust AJ; Dahmus J; Stern B; Soriano C; Rivas G; Hummer B; Kimball SR; Geyer NR; Chinchilli VM; Loomba R; Schmitz K; Sciamanna C
    Hepatology; 2022 Jul; 76(1):172-185. PubMed ID: 34890063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perceptions of Exercise and Its Challenges in Patients With Nonalcoholic Fatty Liver Disease: A Survey-Based Study.
    Glass O; Liu D; Bechard E; Guy CD; Pendergast J; Mae Diehl A; Abdelmalek MF
    Hepatol Commun; 2022 Feb; 6(2):334-344. PubMed ID: 34697917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PNPLA3 genotype increases susceptibility of nonalcoholic steatohepatitis among obese patients with nonalcoholic fatty liver disease.
    Tai CM; Huang CK; Tu HP; Hwang JC; Chang CY; Yu ML
    Surg Obes Relat Dis; 2015; 11(4):888-94. PubMed ID: 25240529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Overview of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis Management].
    Kim SK; Kim KI; Kim SR
    Yakugaku Zasshi; 2019; 139(9):1147-1153. PubMed ID: 31474630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonalcoholic steatohepatitis: global impact and clinical consequences.
    Kabarra K; Golabi P; Younossi ZM
    Endocr Connect; 2021 Oct; 10(10):R240-R247. PubMed ID: 34486981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exercise Reduces Liver Lipids and Visceral Adiposity in Patients With Nonalcoholic Steatohepatitis in a Randomized Controlled Trial.
    Houghton D; Thoma C; Hallsworth K; Cassidy S; Hardy T; Burt AD; Tiniakos D; Hollingsworth KG; Taylor R; Day CP; McPherson S; Anstee QM; Trenell MI
    Clin Gastroenterol Hepatol; 2017 Jan; 15(1):96-102.e3. PubMed ID: 27521509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PPARGC1A rs8192678 G>A polymorphism affects the severity of hepatic histological features and nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease.
    Zhang RN; Shen F; Pan Q; Cao HX; Chen GY; Fan JG
    World J Gastroenterol; 2021 Jul; 27(25):3863-3876. PubMed ID: 34321850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.
    Fracanzani AL; Petta S; Lombardi R; Pisano G; Russello M; Consonni D; Di Marco V; Cammà C; Mensi L; Dongiovanni P; Valenti L; Craxì A; Fargion S
    Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1604-1611.e1. PubMed ID: 28554682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physical deconditioning is the common denominator in both obese and overweight subjects with nonalcoholic steatohepatitis.
    Argo CK; Stine JG; Henry ZH; Lackner C; Patrie JT; Weltman AL; Caldwell SH
    Aliment Pharmacol Ther; 2018 Aug; 48(3):290-299. PubMed ID: 29797529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FibroScan-AST (FAST) Score for Nonalcoholic Steatohepatitis - Validation in an Indian Cohort.
    De A; Keisham A; Mishra S; Mehta M; Verma N; Premkumar M; Taneja S; Das A; Singh V; Duseja A
    J Clin Exp Hepatol; 2022; 12(2):440-447. PubMed ID: 35535068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Web-Based Exercise as an Effective Complementary Treatment for Patients With Nonalcoholic Fatty Liver Disease: Intervention Study.
    Pfirrmann D; Huber Y; Schattenberg JM; Simon P
    J Med Internet Res; 2019 Jan; 21(1):e11250. PubMed ID: 30602434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals.
    Suppli MP; Rigbolt KTG; Veidal SS; Heebøll S; Eriksen PL; Demant M; Bagger JI; Nielsen JC; Oró D; Thrane SW; Lund A; Strandberg C; Kønig MJ; Vilsbøll T; Vrang N; Thomsen KL; Grønbæk H; Jelsing J; Hansen HH; Knop FK
    Am J Physiol Gastrointest Liver Physiol; 2019 Apr; 316(4):G462-G472. PubMed ID: 30653341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The American lifestyle-induced obesity syndrome diet in male and female rodents recapitulates the clinical and transcriptomic features of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Harris SE; Poolman TM; Arvaniti A; Cox RD; Gathercole LL; Tomlinson JW
    Am J Physiol Gastrointest Liver Physiol; 2020 Sep; 319(3):G345-G360. PubMed ID: 32755310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective histopathologic evaluation of lifestyle modification in nonalcoholic fatty liver disease: a randomized trial.
    Eckard C; Cole R; Lockwood J; Torres DM; Williams CD; Shaw JC; Harrison SA
    Therap Adv Gastroenterol; 2013 Jul; 6(4):249-59. PubMed ID: 23814606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-Intensity Interval Training is Safe, Feasible and Efficacious in Nonalcoholic Steatohepatitis: A Randomized Controlled Trial.
    Keating SE; Croci I; Wallen MP; Cox ER; Thuzar M; Pham U; Mielke GI; Coombes JS; Macdonald GA; Hickman IJ
    Dig Dis Sci; 2023 May; 68(5):2123-2139. PubMed ID: 36538276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can Serum Uric Acid Lowering Therapy Contribute to the Prevention or Treatment of Nonalcoholic Fatty Liver Disease?
    Paschos P; Athyros VG; Tsimperidis A; Katsoula A; Grammatikos N; Giouleme O
    Curr Vasc Pharmacol; 2018; 16(3):269-275. PubMed ID: 28676018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.